哮喘急性加重的疾病负担

IF 0.4 Q4 PHARMACOLOGY & PHARMACY

Asian Journal of Pharmaceutics Pub Date : 2020-06-09 DOI:10.22377/ajp.v14i2.3612

M. Iqbal

{"title":"哮喘急性加重的疾病负担","authors":"M. Iqbal","doi":"10.22377/ajp.v14i2.3612","DOIUrl":null,"url":null,"abstract":"Objective: The objective of this study was to determine the direct cost of acute exacerbation of asthma (AEXA) among asthmatic patients. Materials and Methods: A total of 111 asthma patients who were admitted to a public hospital with AEXA included in this study. The costs, including investigation charge, unit costs of treatment per bed, medication charge, food costs, transportation costs, and loss of productivity per asthma episode, were calculated. Data were analyzed using Statistical Package for the Social Sciences (SPSS) ver.23.0. Results: A median medical cost of AEXA under the government perspective was USD 105.00 per episode. Medication cost comprised the majority (52.38%) of the total medical costs and lab investigations. A median medical cost of AEXA under the patient’s perspective was USD 22.50 per episode. Conclusion: AEXA and total days stay in the hospital were directly proportional to the total direct costs.","PeriodicalId":8489,"journal":{"name":"Asian Journal of Pharmaceutics","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2020-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"The Burden of Illness of Acute Exacerbation of Asthma\",\"authors\":\"M. Iqbal\",\"doi\":\"10.22377/ajp.v14i2.3612\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: The objective of this study was to determine the direct cost of acute exacerbation of asthma (AEXA) among asthmatic patients. Materials and Methods: A total of 111 asthma patients who were admitted to a public hospital with AEXA included in this study. The costs, including investigation charge, unit costs of treatment per bed, medication charge, food costs, transportation costs, and loss of productivity per asthma episode, were calculated. Data were analyzed using Statistical Package for the Social Sciences (SPSS) ver.23.0. Results: A median medical cost of AEXA under the government perspective was USD 105.00 per episode. Medication cost comprised the majority (52.38%) of the total medical costs and lab investigations. A median medical cost of AEXA under the patient’s perspective was USD 22.50 per episode. Conclusion: AEXA and total days stay in the hospital were directly proportional to the total direct costs.\",\"PeriodicalId\":8489,\"journal\":{\"name\":\"Asian Journal of Pharmaceutics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2020-06-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Asian Journal of Pharmaceutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.22377/ajp.v14i2.3612\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Journal of Pharmaceutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22377/ajp.v14i2.3612","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 2

摘要

目的:本研究的目的是确定哮喘患者急性发作(AEXA)的直接成本。材料与方法:本研究共纳入公立医院收治的111例AEXA哮喘患者。计算成本，包括调查费用、每张病床的单位治疗费用、药物费用、食品费用、运输费用和每次哮喘发作的生产力损失。数据分析使用社会科学统计软件包(SPSS) ver.23.0。结果:政府视角下AEXA的平均医疗费用为105.00美元/次。用药费用占总医疗费用和实验室调查费用的52.38%。在患者的视角下，AEXA的平均医疗费用为22.50美元/次。结论:AEXA和总住院天数与总直接费用成正比。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The Burden of Illness of Acute Exacerbation of Asthma

Objective: The objective of this study was to determine the direct cost of acute exacerbation of asthma (AEXA) among asthmatic patients. Materials and Methods: A total of 111 asthma patients who were admitted to a public hospital with AEXA included in this study. The costs, including investigation charge, unit costs of treatment per bed, medication charge, food costs, transportation costs, and loss of productivity per asthma episode, were calculated. Data were analyzed using Statistical Package for the Social Sciences (SPSS) ver.23.0. Results: A median medical cost of AEXA under the government perspective was USD 105.00 per episode. Medication cost comprised the majority (52.38%) of the total medical costs and lab investigations. A median medical cost of AEXA under the patient’s perspective was USD 22.50 per episode. Conclusion: AEXA and total days stay in the hospital were directly proportional to the total direct costs.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Asian Journal of Pharmaceutics PHARMACOLOGY & PHARMACY-

自引率

0.00%

发文量

期刊介绍： Character of the publications: -Pharmaceutics and Pharmaceutical Technology -Formulation Design and Development -Drug Discovery and Development Interface -Manufacturing Science and Engineering -Pharmacokinetics, Pharmacodynamics, and Drug Metabolism -Clinical Pharmacology, General Medicine and Translational Research -Physical Pharmacy and Biopharmaceutics -Novel Drug delivery system -Biotechnology & Microbiological evaluations -Regulatory Sciences